Women’s health therapeutics market has been a very promising market in the healthcare industry, since every woman faces a gynecological disorder at some point in her life. Several of these disorders are treatable and many others are fatal, if proper timely treatment is not received.
Therefore, women health therapeutics market is attracting numerous pharmaceutical companies which are evident from their increased research and development efforts, and the robust pipeline candidates available. The global women therapeutics market has continued to grow in the last decade due to increasing awareness among patients and physicians, and the introduction of more effective novel therapies in the market.
The global women health therapeutics market can be segmented on the basis of treatment for applications such as menopause related disorders, postmenopausal osteoporosis, infertility, endometriosis, gynecological cancer, polycystic ovary syndrome and birth control. Among these application segments, the menopause related disorders segment and post menopause osteoporosis market segment are expected to have maximum growth potential in women health therapeutics market during the forecast period from 2014 to 2015. Osteoporosis is a major concern among post-menopausal women and this disease is estimated to affect approximately 20 percent of post-menopausal women. The disease is characterized by significant loss of bone mass and increasing the risk of serious fractures. Currently the menopause therapeutics market is driven by hormone therapeutics, which is less health concerned. New entrance of non-hormones therapeutics is expected to compete with the currently marketed drugs and will significantly change the market dynamics. Some of the major marketed drugs include Evista (Eli Lilly Company), Xgeva (Amgen, Inc.), Mirena (Bayer AG), Zometa (Novartis AG), Minastrin 24FE (Actavis plc), Nuvaring (Merck), Forteo, Premarin, Actonel, Ortho-Tri-Cy Lo 28 and Reclast. Breast cancer therapeutics is the most important segment in the women therapeutics market. High cost of drugs has been the key factor driving the market.
On the basis of geography, the global women health therapeutics market has been segmented in to four major regions, North America, Europe, Asia Pacific and Rest of the World. Globally, North America and Europe represent the leading markets for women health therapeutics owing to growing elderly population and increased awareness regarding women health. Emerging economies of Asia Pacific, Middle East and Latin America are expected to show rapid growth in the market due to high incidences of urological disorders and increase in awareness of women seeking such treatments frequently. Changing life style and government initiatives to increase awareness regarding women healthcare facilities have also supported the market.
The current women health therapeutics market has strong pipeline with promising molecules in clinical development such as ASP1707, abaloparatide, AZD4901, elagolix, odanacatib (MK-0822), romosozumab (AMG785), recombinant oral salmon calcitonin, teriparatide, vaginorm, etc. These pipeline molecules are expected to drive the global women therapeutics market in terms of volume. Thus there are ample opportunities for new non hormone therapeutics drugs in women health therapeutics market for new as well as existing players. Although branded drugs have more opportunities in the developed nations, advent of generic drugs post patent expiry will drive the market in low and middle income countries.
Some of the key companies in the global women health therapeutics market include Abbott Laboratories, Actavis plc, Amgen, Inc., AstraZeneca plc, Bayer AG, Eli Lilly Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.